The next chapter of innovation in medicine is being written in Asia. Long seen as the workhorse for manufacturing, generics, and back-end execution, the region has become a powerhouse of pharmaceutical innovation, fueled by a rapidly expanding base of world-class research. Asia now accounts for roughly 43 percent of the global innovative pipeline and 40 percent of out-licensing activity. And between 2021 and 2025, Asia’s pace of publishing in top biomedical journals surged to nearly 10 percent annually—more than triple that of both Europe and the United States.
These shifts reflect deep, structural forces that are only accelerating. McKinsey’s new report, “Asia biopharma: At the frontier of rewiring global innovation,” draws on proprietary data and expert interviews to map the region’s rise, examine the distinctive features of its innovation landscape, and identify the implications for innovators, multinational pharmaceutical companies, and investors.
Five insights stand out:
- Asia is a prime source for next-generation therapies. Greater China is the region’s dominant contributor to the global pipeline, with South Korea delivering rapid growth and Japan contributing selective depth in basic science and advanced therapeutics. Momentum is particularly strong in next-generation modalities, such as cell and gene therapy, antibody-drug conjugates, bispecific antibodies, and nucleic-acid platforms; these modalities now represent a third of Asia-originated assets. Clinical programs originating in Asia are also advancing into later stages faster than those from the United States or Europe, reflecting improving asset quality and execution maturity.
- The best deals in Asia go to those who show up early. Asia accounts for roughly 40 percent of global out-licensing transactions, concentrated in oncology and next-generation modalities. Most assets are licensed pre–Phase II, a consequence of strong demand from Western partners and a persistent lack of late-stage capital within the region. Deal structures are shifting from single-asset transactions toward multi-asset transactions and platform-based partnerships, increasingly comparable in ambition and scale to Western platform deals. Companies that engage too late risk losing access, paying a premium, and ceding strategic control.
- Asia’s R&D advantage is also about speed and scale, not just efficiency. The case for embedding Asia into global R&D models is no longer primarily about cost. Large, concentrated patient populations, dense contract-research-organization and site-management-organization ecosystems, and an expanding base of qualified clinical sites and principal investigators particularly in China and South Korea, are translating into faster trials and execution efficiency at a scale difficult to match elsewhere. These capabilities, along with momentum in AI-driven discovery across the region and India’s emergence as a strategic R&D hub, are compressing timelines and raising the ceiling on what Asia-embedded R&D models can deliver.
- Uneven funding is creating alpha investment opportunities in Asia. Despite originating more than 40 percent of new molecular assets, Asia attracts only about 10 percent of global private equity and venture capital investment. That 10 percent is heavily concentrated in China and skewed toward early stages. Late-stage funding gaps, particularly in Japan and South Korea, continue to push high-quality assets toward early out-licensing and constrain companies’ ability to scale independently. For investors, this imbalance creates an opportunity—best pursued through capital-efficient, partnership-led models—to capture above-market returns from high-value assets facing less investor competition.
- Leading companies aren’t just making deals in Asia—they’re building there. Leading multinationals are moving beyond transactional licensing toward integrating complementary capabilities across Asia. This includes AI-driven discovery and CRO-enabled execution in China, biologics manufacturing in South Korea, and APIs and formulation in India. Also, many organizations are pursuing broader co-development agreements with global pharmaceutical leaders and established Japanese firms. Regional partnerships, which include emerging markets in Latin America and Africa, are also gaining traction as companies seek to maximize the reach of these new assets.
For Asia-based innovators, the next frontier is a shift from single-asset out-licensing to an integrated “global mesh” R&D model. Rather than simply relocating functions, companies can selectively draw on the most competitive regional capabilities, whether full stages of discovery or specialized workflows. This model enables the establishment of a sustainable, multi-asset innovation engine that maximizes speed, depth, and differentiation while securing greater strategic control and global reach.
For the full report, see “Asia biopharma: At the frontier of rewiring global innovation.”
The authors wish to thank Aeri Yeo, Alex Zhao, Anirudh Roy Popli, Jacob Li, Jin Ji, Josie Zhou, Khevan Somasundram, Kyungmin Lee, Tin Yat Yeng, and Tomoko Nagatani for their contributions to this blog post.